ConductScience.org, home

Paper30135355

Epigallocatechin-3-gallate and 6-OH-11-O-Hydroxyphenanthrene Limit BE(2)-C Neuroblastoma Cell Growth and Neurosphere Formation In Vitro.

Farabegoli F and 3 others. Nutrients, 2018. Cited by 9 papers, by iCite.

Cite this record

ConductScience Library. Epigallocatechin-3-gallate and 6-OH-11-O-Hydroxyphenanthrene Limit BE(2)-C Neuroblastoma Cell Growth and Neurosphere Formation In Vitro. Papers, record 30135355. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/30135355

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Epigallocatechin-3-gallate and 6-OH-11-O-Hydroxyphenanthrene Limit BE(2)-C Neuroblastoma Cell Growth and Neurosphere Formation In Vitro.
PubMed
Journal
Nutrients
PubMed
Year
2018
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
9
iCite
Relative citation ratio, by iCite
0.37
iCite
Revised in PubMed
2019-01-15
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Farabegoli FFulvia
2Govoni MMarziahttps://orcid.org/0000-0003-1673-0107
3Spisni EEnzo
4Papi AAlessio

Source PubMed

Download CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
CatechinMajor topic
Neoplastic Stem CellsMajor topic
NeuroblastomaMajor topic
PhenanthrenesMajor topic
Apoptosis
Cell Line, Tumor
Cell Survival
Drug Synergism
Gene Expression Regulation, Neoplastic
Genes, myc
Humans
Matrix Metalloproteinase 2
Matrix Metalloproteinase 9
Tea

Source PubMed

Download CSV of topics

References38

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
129062613Emerging and investigational therapies for neuroblastoma.Expert Opin Orphan Drugs2017https://conductscience.org/library/papers/29062613PubMed
220558371Recent advances in neuroblastoma.N Engl J Med2010https://conductscience.org/library/papers/20558371PubMed
324086065Neuroblastoma and MYCN.Cold Spring Harb Perspect Med2013https://conductscience.org/library/papers/24086065PubMed
425013807A RXR ligand 6-OH-11-O-hydroxyphenanthrene with antitumour properties enhances (-)-epigallocatechin-3-gallate activity in three human breast carcinoma cell lines.Biomed Res Int2014https://conductscience.org/library/papers/25013807PubMed
526534963The Metastasis Suppressor, N-MYC Downstream-regulated Gene-1 (NDRG1), Down-regulates the ErbB Family of Receptors to Inhibit Downstream Oncogenic Signaling Pathways.J Biol Chem2016https://conductscience.org/library/papers/26534963PubMed
619212680Retinoids induce differentiation and downregulate telomerase activity and N-Myc to increase sensitivity to flavonoids for apoptosis in human malignant neuroblastoma SH-SY5Y cells.Int J Oncol2009https://conductscience.org/library/papers/19212680PubMed
729764159Emerging role of immunotherapy for childhood cancers.Chin Clin Oncol2018https://conductscience.org/library/papers/29764159PubMed
820332466Epigenetic modifiers as anticancer drugs: effectiveness of valproic acid in neural crest-derived tumor cells.Anticancer Res2010https://conductscience.org/library/papers/20332466PubMed
919893570BH3 response profiles from neuroblastoma mitochondria predict activity of small molecule Bcl-2 family antagonists.Cell Death Differ2010https://conductscience.org/library/papers/19893570PubMed
1012820415Effect of a new derivative of retinoic acid on proliferation and differentiation in human neuroblastoma cells.Anticancer Res2003https://conductscience.org/library/papers/12820415PubMed
1121909813Epigallocatechin gallate inhibits sphere formation of neuroblastoma BE(2)-C cells.Environ Health Prev Med2012https://conductscience.org/library/papers/21909813PubMed
1212880980Retinoid therapy of high-risk neuroblastoma.Cancer Lett2003https://conductscience.org/library/papers/12880980PubMed
1328840597Retinoic acid postconsolidation therapy for high-risk neuroblastoma patients treated with autologous haematopoietic stem cell transplantation.Cochrane Database Syst Rev2017https://conductscience.org/library/papers/28840597PubMed
1426729169Cancer Stem Cells and Their Interaction with the Tumor Microenvironment in Neuroblastoma.Cancers (Basel)2015https://conductscience.org/library/papers/26729169PubMed
1528465354EGFR inhibition by (-)-epigallocatechin-3-gallate and IIF treatments reduces breast cancer cell invasion.Biosci Rep2017https://conductscience.org/library/papers/28465354PubMed
1629445860Origin and initiation mechanisms of neuroblastoma.Cell Tissue Res2018https://conductscience.org/library/papers/29445860PubMed
1722498172Alterations in expression of specific microRNAs by combination of 4-HPR and EGCG inhibited growth of human malignant neuroblastoma cells.Brain Res2012https://conductscience.org/library/papers/22498172PubMed
1821796439A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma.Invest New Drugs2012https://conductscience.org/library/papers/21796439PubMed
1922941525Retinoids in pediatric onco-hematology: the model of acute promyelocytic leukemia and neuroblastoma.Adv Ther2012https://conductscience.org/library/papers/22941525PubMed
2016890796New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.Semin Oncol2006https://conductscience.org/library/papers/16890796PubMed

See all 38 referencesDownload CSV of references

Cited by8

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.

PMIDTitleJournalYearIn PapersSource
42764445A Hybrid Bioprinting-Microfabrication Approach to Controllable Multitype Spheroid Arrays for Modeling Tumor Heterogeneity.Adv Healthc Mater2026https://conductscience.org/library/papers/42764445PubMed
39804528Emerging Trends in Neuroblastoma Diagnosis, Therapeutics, and Research.Mol Neurobiol2025https://conductscience.org/library/papers/39804528PubMed
38243984The Potential of Epigallocatechin Gallate in Targeting Cancer Stem Cells: A Comprehensive Review.Curr Med Chem2024https://conductscience.org/library/papers/38243984PubMed
37450923MYC Oncogene: A Druggable Target for Treating Cancers with Natural Products.Aging Dis2024https://conductscience.org/library/papers/37450923PubMed
36677584Effects of Epigallocatechin-3-Gallate on Matrix Metalloproteinases in Terms of Its Anticancer Activity.Molecules2023https://conductscience.org/library/papers/36677584PubMed
36362917Nutraceutical Preventative and Therapeutic Potential in Neuroblastoma: From Pregnancy to Early Childhood.Life (Basel)2022https://conductscience.org/library/papers/36362917PubMed
31867574Cancer stem cells in neuroblastoma therapy resistance.Cancer Drug Resist2019https://conductscience.org/library/papers/31867574PubMed
31027187Tea in Health and Disease.Nutrients2019https://conductscience.org/library/papers/31027187PubMed

Download CSV of cited by

Genes16

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/30135355

GET https://conductscience.org/api/papers/v1/30135355/references?page=2